ABC294640

DRUG4 trials

Sponsors

RedHill Biopharma Limited, Medical University of South Carolina

Conditions

Carcinoma, HepatocellularCholangiocarcinomaCholangiocarcinoma Non-resectableCholangiocarcinoma, ExtrahepaticCholangiocarcinoma, IntrahepaticCholangiocarcinoma, PerihilarDiffuse Large B Cell LymphomaKaposi Sarcoma

Phase 1

Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma

WithdrawnNCT02229981

RedHill Biopharma LimitedDiffuse Large B Cell Lymphoma, Kaposi Sarcoma

Start: 2014-07-31End: 2019-12-31Updated: 2017-12-07

Phase 2

A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma

WithdrawnNCT02939807

Medical University of South CarolinaCarcinoma, Hepatocellular

Start: 2019-09-30End: 2024-01-30Updated: 2025-04-27

A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma

CompletedNCT03377179

RedHill Biopharma LimitedCholangiocarcinoma, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic +2

Start: 2018-03-07End: 2022-06-21Updated: 2025-07-23

Unknown Phase

Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)

RedHill Biopharma LimitedCholangiocarcinoma, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic +2

Updated: 2025-03-18